# Table 5 Summary of the validation with data set 1

MIX STATA/CMA *
Items in odds ratio meta-analysis Results Results
Fixed effect (IV) odds ratio
OR – IV (95% CI) 0.7677 (0.7196 to 0.8190) 0.7677 (0.7196 to 0.8190)
Z (P value) 8.0073 (< 0.0001) 8.01 (< 0.0001)
Q (P value) 39.48 (0.17) 39.48 (0.17)
I2 (95% CI) 0.1895 (0 to 0.4749) 0.1895
Fail-safe N (tolerance level) 270 (175) 270 *
Rank correlation tau ** (P value) 0.1799 (0.141) (0.141)
Egger's regression intercept (95% CI) -0.2955 (-0.7880 to 0.1970) -0.2955 (-0.7880 to 0.1970)
Macaskill's regression slope (P value) 0 (0.8396) 0 (0.840)
Trim-and-fill association measure (95% CI) 0.7744 (0.7260 to 0.8260) 0.774 (0.726 to 0.826)
Trim-and-fill imputed studies 6 6
Random effects (IV + t) odds ratio
OR – IV + t (95% CI) 0.7619 (0.6825 to 0.8506) 0.7619 (0.6825 to 0.8506)
Z (P value) -4.84 (< 0.0001) -4.84 (< 0.0001)
t2 0.117 0.117
Trim-and-fill association measure (95% CI) 0.7828 (0.6907 to 0.8871) 0.783 (0.691 to 0.887)
Trim-and-fill imputed studies 6 6
1. This table shows the odds ratio validation of the inverse variance fixed effect and random effects analyses with data set 1. Though not shown here, the results from Mantel-Haenszel and Peto weighting were evaluated similarly and so were the other association measures (risk difference and risk ratio). The process was repeated for each data set. (*): Results marked with '*' were produced by CMA. (**): The rank correlation tau is a continuity corrected tau-b. Abbreviations: "IV" = inverse variance weighting, "OR" = odds ratio, "CI" = confidence interval, "IV+t" = inverse variance plus tau, which refers to random effects weighting according to the DerSimonian-Laird method.
{"ft_lang_label":"__label__en","ft_lang_prob":0.7019253,"math_prob":0.939136,"size":1128,"snap":"2020-34-2020-40","text_gpt3_token_len":488,"char_repetition_ratio":0.13967972,"word_repetition_ratio":0.034883723,"special_character_ratio":0.5833333,"punctuation_ratio":0.19081272,"nsfw_num_words":0,"has_unicode_error":false,"math_prob_llama3":0.9630937,"pos_list":[0],"im_url_duplicate_count":[null],"WARC_HEADER":"{\"WARC-Type\":\"response\",\"WARC-Date\":\"2020-08-08T15:41:31Z\",\"WARC-Record-ID\":\"<urn:uuid:ed36c4ff-eb14-4187-9980-c65dfcb73bf7>\",\"Content-Length\":\"90149\",\"Content-Type\":\"application/http; msgtype=response\",\"WARC-Warcinfo-ID\":\"<urn:uuid:6767152d-a0ab-4638-8554-a6c36f9a1bde>\",\"WARC-Concurrent-To\":\"<urn:uuid:9cdf9d6c-ad14-4883-a266-ef9ae6dfca5e>\",\"WARC-IP-Address\":\"199.232.64.95\",\"WARC-Target-URI\":\"https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-6-50/tables/5\",\"WARC-Payload-Digest\":\"sha1:KFUYRHET4YKOLFRCIK3P5WGL72CWHESZ\",\"WARC-Block-Digest\":\"sha1:SVKS3FDRYUMS2ZU6JISKCMMIA7QFTF6L\",\"WARC-Identified-Payload-Type\":\"text/html\",\"warc_filename\":\"/cc_download/warc_2020/CC-MAIN-2020-34/CC-MAIN-2020-34_segments_1596439737883.59_warc_CC-MAIN-20200808135620-20200808165620-00094.warc.gz\"}"}